For example, low-dose chemotherapeutic agents, including oxaliplatin, are capable of upregulating ligands for the activating receptors NKG2D and DNAX accessory molecule-1 (DNAM-1; CD226) and TRAIL in multiple tumor lines leading to enhanced susceptibility to NK cell cytotoxicity (Soriani et al., 2009; Siew et al., 2015). This evidence concerns the gene KLRK1 and neoplasm.